Search FOXO4-DRI dosage and you will find charts, protocols and confident milligram figures. None of them rest on anything. There is no established human dose for this peptide, because no human being has received it in a registered clinical trial, and ClinicalTrials.gov lists no such study. Any dosing chart you encounter was authored by someone extrapolating from mouse experiments, and this page is not going to add another one.
Key takeaways
- Zero human trials of FOXO4-DRI have been registered or published, so there is no human dose, no human pharmacokinetics, and nothing to titrate against.
- The foundational mouse work used 5 mg/kg given three times on alternating days, days 1, 3 and 5. That is a mouse dose from a mouse experiment.
- Body-weight scaling from rodents is not a licence to compute a human figure, and for this compound the inputs that scaling requires do not exist.
- The vial arithmetic is where a genuine, checkable error lives: measured net content on two published batches was 11.41 mg and 8.30 mg against a 10 mg label.
- Reconstituting on the label assumption can leave your working concentration roughly 17% off before anything else happens.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
FOXO4-DRI dosage: why the honest answer is that there is not one
An established dose is not simply a number somebody has used. It is a number that survived dose-ranging studies, pharmacokinetic sampling, a safety review and, eventually, a regulator. Every step of that process is missing here.
FOXO4-DRI has no marketing authorisation from the FDA, the EMA or the MHRA. It has no approved indication and no drug label. There is no phase 1 trial establishing how it behaves in a human body, no maximum tolerated dose, no half-life measured in people, and no adverse-event dataset. The compound sits where it sat in 2017: a promising result in animals that has not been carried into human testing.
That is why this article gives you the published animal figures and the vial arithmetic instead of a chart. Those are the two things that are actually known.
What the published work used
The foundational study is Baar and colleagues, Cell, 2017, from the de Keizer group at Erasmus MC. Its dosing is stated plainly in the paper.
In the chemotoxicity experiments, mice received FOXO4-DRI at 5 mg/kg, three times, on alternating days: day 1, day 3 and day 5, given intravenously. In the ageing cohorts, including the fast-ageing XpdTTD/TTD strain and naturally aged animals, administration was intraperitoneal. Doxorubicin, the chemotherapeutic used to induce senescence in that model, was given separately at 10 mg/kg in mice.
Two features of that schedule are worth noting because they are frequently misdescribed. First, it is intermittent rather than continuous. Three doses on alternating days is a short burst, not an ongoing regimen. Second, the administration routes used in mice, intravenous and intraperitoneal, are laboratory routes. Intraperitoneal injection is not a route used in human medicine outside specific clinical circumstances.
Later work has used its own dosing in its own models: aged mouse Leydig cells, murine pulmonary fibrosis, keloid fibroblasts, cultured human chondrocytes. Each study set doses for its own system. None of it was a dose-finding exercise for people.
Why a mouse figure does not convert
The reflex is to take 5 mg/kg, multiply by a body weight, and apply a scaling factor. Interspecies allometric scaling is a real method, but it is a method for estimating a starting point for further study, not for producing a usable dose. It also requires inputs this compound does not have.
Scaling assumes you know how the compound is absorbed, distributed, metabolised and cleared in the target species. For FOXO4-DRI in humans, none of those are known. There is no measured half-life, no bioavailability figure, no clearance route, no distribution volume. A D-retro-inverso peptide is specifically engineered to resist protease degradation, which is likely to change its persistence relative to an ordinary peptide, and by how much in a human body is unstudied.
There is also the question of what dose you would even be aiming at. The mouse experiments measured senescent-cell clearance in specific tissues under specific stressors. The relationship between a dose that clears senescent cells in a mouse liver and any human outcome is not established, because no human outcome has been measured.
So the arithmetic can be performed. It just does not produce knowledge.
The vial arithmetic, and the assumption that breaks it
Here is the part that is genuinely actionable, and where a real error is being made routinely.
Reconstitution maths is simple: mass divided by volume gives concentration. Put 2 mL of bacteriostatic water into a vial holding 10 mg and you have 5 mg/mL. The problem is the first number.
Ascension publishes two certificates for FOXO4-DRI, from two laboratories, covering two different batches. Kovera Labs measured batch 55-05260628 at 11.41 mg of net content. MZ Biolabs measured lot 55-01260229 at 8.30 mg. Both vials carried a 10 mg label, and both tested above 99% pure. Purity and quantity are separate measurements, and it is the quantity that moved.
| Assumed or measured content | Reconstituted in 2 mL | Reconstituted in 1 mL |
|---|---|---|
| 10 mg, from the label | 5.00 mg/mL | 10.00 mg/mL |
| 11.41 mg, Kovera batch | 5.71 mg/mL | 11.41 mg/mL |
| 8.30 mg, MZ Biolabs lot | 4.15 mg/mL | 8.30 mg/mL |
Anyone calculating from the label while holding the January batch is working with a concentration roughly 17% below what they wrote down. Every volume drawn inherits that error, and no amount of careful measurement downstream corrects an incorrect starting mass.
The practical instruction that follows is simple: use the net content figure from the certificate matching the lot number on your vial, not the number printed on the label. If you were not given a lot-matched certificate, ask for one. The peptide calculator will handle the arithmetic accurately once you give it the right input, and the same label-versus-measured problem is worked through for NAD injections, where the quantities are larger and the discrepancy proportionally easier to see.
Handling and stability
The lyophilised powder is the stable form, which is why it ships dry and why a parcel arriving at ambient temperature is not a problem. Stored cool, dark and sealed, dry peptide is comparatively durable.
Once reconstituted, the situation changes. Peptides in solution degrade, and the rate depends on temperature, pH, agitation and the number of freeze-thaw cycles. Bacteriostatic water contains a preservative that permits repeated withdrawals from the same vial, which sterile water does not. Reconstituted material belongs refrigerated, and it should not be shaken; the solvent is directed against the vial wall and the vial swirled rather than agitated, because mechanical stress denatures peptides.
None of that is dosing advice. It is handling, and it applies to laboratory material as laboratory material.
Frequently asked questions
What is the correct FOXO4-DRI dosage?
There is no correct human dosage, because the compound has never been tested in a registered human trial. No regulator has reviewed it, no phase 1 study has established tolerability, and no human pharmacokinetic data exists. Charts circulating online are extrapolations from rodent experiments rather than established doses.
What dose did the mouse studies use?
The 2017 Cell paper gave mice 5 mg/kg three times on alternating days, days 1, 3 and 5, intravenously in the chemotoxicity experiments and intraperitoneally in the ageing cohorts. Those are mouse doses via laboratory routes, reported here as what the experiment did rather than as a basis for calculation.
Can I convert the mouse dose using body-weight scaling?
You can perform the calculation, but it does not yield a validated dose. Allometric scaling estimates a starting point for formal study and needs pharmacokinetic inputs that do not exist for this peptide in humans: no measured half-life, no bioavailability, no clearance data. The output would be a number without evidence behind it.
How much peptide is actually in a 10 mg vial?
It varies by batch, which is the most useful thing on this page. The two published certificates measured 11.41 mg and 8.30 mg in vials labelled 10 mg. Work from the certificate matching your lot number, because reconstituting on the label assumption can put your concentration out by roughly 17%.
How should reconstituted FOXO4-DRI be stored?
Refrigerated, protected from light, and not agitated. Bacteriostatic water rather than sterile water allows repeated withdrawals. The dry powder is far more stable than the solution, so material is best left lyophilised until it is going to be used.